Navigation Links
Cepheid Reports Fourth Quarter and Full Year 2007 Results
Date:2/28/2008

Clinical Sales Growth of 211 Percent Highlights Company Transition to

Clinical Market

SUNNYVALE, Calif., Feb. 28 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today announced financial results for the fourth quarter and full year ended December 31, 2007.

Key results for the full year 2007:

-- Total revenues of $129.5 million, a 48 percent increase from

$87.4 million for the full year of 2006

- Total product sales of $116.5 million, a 41 percent increase from

$82.4 million for the full year of 2006

* Clinical product sales of $61.0 million, a 211 percent

increase from $19.6 million for the full year of 2006

-- Cumulative total of 2,008 diagnostic modules of the GeneXpert(R) System

installed in U.S. accounts and 561 installed in Europe as of

December 31, 2007

-- Net loss, excluding stock compensation expense and the amortization of

acquired intangibles, of $9.3 million, or $0.17 per share, compared to

$18.6 million, or $0.36 per share, for the full year 2006

"The year 2007 was a break-out year for Cepheid as we realized significant market traction with the only fully integrated system for on-demand PCR-based DNA testing in the clinical market," said John Bishop, Cepheid's Chief Executive Officer. "Moving into 2008, our momentum continues with the expansion of worldwide market penetration of the GeneXpert System into the three key MRSA market segments: surveillance, diagnosis and pre-surgical testing. We also expect to see expansion into additional Healthcare-Associated Infection (HAI) markets including tests for Vancomycin-resistant Enterococci (VRE) and C. difficile. We will also focus on expanding our test menu to address additional high-margin clinical segments, including oncology."

Fourth Quarter and Full Year 2007 Results:

Total revenues of $40.4 m
'/>"/>

SOURCE Cepheid
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Cepheid and Instrumentation Laboratory Introduce Xpert(TM) HemosIL(R) FII & FV Assay to European Clinical Testing Market
2. Cepheid Appoints Senior VP, Chief Financial Officer to Management Team
3. Cepheid Schedules Teleconference and Webcast for 2007 Fourth Quarter and Full Year Results
4. Cepheid Receives Health Canada Medical Device License for Xpert MRSA(TM) Test and GeneXpert(R) System
5. Cepheid to Present at the Piper Jaffray 19th Annual Healthcare Conference
6. Cepheid to Present at William Blair Small-Cap Growth Stock Conference
7. Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB
8. Cepheid to Present at Thomas Weisel Partners Healthcare Conference
9. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
10. Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results
11. US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... 2015 W. R. Grace & ... in Worms, Germany has received good manufacturing practice ... the International Pharmaceutical Excipient Council (IPEC) Foundation. ... its SYLOID® FP brand of pharmaceutical grade excipient ... the Curtis Bay, Maryland (USA) and Sorocaba, Brazil ...
(Date:5/21/2015)... As part of its philanthropic partnership with Banner ... funded a $3.25 million project to relocate and equip ... up-to-date features and technology. , The new pharmacy is ... members will begin moving from the current location to ... , The current pharmacy has been using a ...
(Date:5/21/2015)... (PRWEB) May 21, 2015 Veolia’s ... an exclusive North American distribution agreement with VWR ... system. , With more than 160 years of ... and services for laboratory and production facilities, has ... excellence and differentiated services to enable science. ...
(Date:5/20/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/x4b7kw/top_technologies ... Technologies in HW_Technical Insights" report to their offering. ... technology trends in the Health and Wellness sector and ... have an impact in the year 2015. The research ... 10 health and wellness technologies that are anticipated to ...
Breaking Biology Technology:Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 3Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2Top Technologies in the Health and Wellness Industry 2015 2
... VIEW, Calif., Jan. 26 Based on its ... & Sullivan recognizes ESBATech with the 2009 North ... Year Award for its work in developing antibody ... antibody fragment therapeutics addresses and overcomes many of ...
... (OTC Bulletin Board: PDAE) today announced that its Hereford ... under Chapter 11 of the United States Bankruptcy Code ... District of Texas. The company intends to sell its ... Section 363 sale process approved by the bankruptcy court. ...
... JOLLA, Calif., Jan. 23 Cordex Pharma, Inc., formerly known ... that it will host a scientific briefing on Thursday, January ... The keynote speaker will be Jonathan S. Stamler, MD, the ... a Professor of Medicine and of Biochemistry at Duke ...
Cached Biology Technology:Frost & Sullivan Recognizes ESBATech's Innovation in Developing Antibody Fragments for Biologic Therapeutics 2Frost & Sullivan Recognizes ESBATech's Innovation in Developing Antibody Fragments for Biologic Therapeutics 3Frost & Sullivan Recognizes ESBATech's Innovation in Developing Antibody Fragments for Biologic Therapeutics 4Panda Ethanol's Hereford, Texas Subsidiary Files Voluntary Chapter 11 2Panda Ethanol's Hereford, Texas Subsidiary Files Voluntary Chapter 11 3Cordex Pharma Presents 'New Frontiers in Cardiovascular Medicines' on January 29 2Cordex Pharma Presents 'New Frontiers in Cardiovascular Medicines' on January 29 3Cordex Pharma Presents 'New Frontiers in Cardiovascular Medicines' on January 29 4Cordex Pharma Presents 'New Frontiers in Cardiovascular Medicines' on January 29 5
(Date:5/20/2015)... DUBLIN , May 20, 2015 ... Markets ( http://www.researchandmarkets.com/research/h8t4x6/5year ) has announced the ... of the Global Iris Recognition Market" ... http://photos.prnewswire.com/prnh/20130307/600769) , ,This research service analyses ... across the government and commercial sectors, ...
(Date:5/18/2015)... Fingerprint Cards (FPC) has received an ... and FPC1035 from one if its module partners. Deliveries are ... 2015 and the sensors will be used by smartphone manufacturers ... 2015 hereby amount to 740 MSEK to date. In addition ... and a number of smaller orders not separately communicated amounting ...
(Date:5/11/2015)... N.Y. , May 11, 2015 Curemark ... announced the start of a new Phase III double ... of its novel formulation, CM-AT, on all children ages ... of its FDA Phase III double blinded clinical trial ... had low levels of the digestive enzyme chymotrypsin. This ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... PITTSBURGHCarnegie Mellon University researchers have found that within ... neurons that behave much like people in social networks. ... of highly active members who give and receive more ... Barth, associate professor of biological sciences at Carnegie Mellon ...
... 10, 2011 Cleveland Researchers have discovered a ... undergo testing for genetic mutations of the tumor suppressor ... including several types of cancers. The research has created ... Led by Charis Eng, M.D., Ph.D., Chair of ...
... (January 9, 2011) - While age-related vision loss of ... million patients today to 55 million by the year 2050, ... vision even restored using molecular medicine. ... at the 10th annual meeting and International Conference on Recent ...
Cached Biology News:Carnegie Mellon researchers identify 'Facebook neurons' 2Carnegie Mellon researchers identify 'Facebook neurons' 3Researchers create 'scoring system' for PTEN mutation testing 2Molecular medicine could avert predicted catastrophic vision loss in the aged 2Molecular medicine could avert predicted catastrophic vision loss in the aged 3
Viral CMV UL146/vCXC1 Biotinylated Affinity Purified PAb...
Request Info...
D-biotin *50 mM aqueous solution* Secondary Detection Biotin–Avidin Detection Reagents Other...
... strains are high-performance BL21 ... protein yield in T7 ... 1). Because the T7 ... more rapidly than E. ...
Biology Products: